-
Monomethyl auristatin is any of a
group of
synthetic antineoplastic agents derived from the sea slug
Dolabella auricularia:
Monomethyl auristatin E Monomethyl...
-
Monomethyl auristatin E (MMAE) is a
synthetic antineoplastic agent.
Because of its toxicity, it
cannot be used as a drug itself; instead, it is linked...
-
Monomethyl auristatin F (MMAF) is a
synthetic antineoplastic agent. It is part of the
approved drug
belantamab mafodotin in
multiple myeloma and some experimental...
-
spacers to
three to five
units of the
antimitotic agent monomethyl auristatin E (MMAE,
reflected by the 'vedotin' in the drug's name). The peptide-based...
- G1
antibody that is
linked to the
antitumor agent vedotin (monomethyl
auristatin E). In China,
disitamab vedotin was
approved in 2021 for the treatment...
- An antibody-drug
conjugate (ADC) with a
strong cytotoxin,
monomethyl auristatin E,
designed to
treat EGFR-positive tumors,
including those with KRAS and...
-
Payloads include the
microtubulin inhibitors monomethyl auristatin E (MMAE),
monomethyl auristatin F (MMAF) and mertansine, DNA
binder calicheamicin and...
-
Brentuximab Vedotin (SGN-35)
Adcetris Mollusk Antibody-Drug
Conjugate (MM
Auristatin E) CD30 and
Microtubules 9/19
Cancer Plitidepsin Aplidin Tunicate Depsipeptide...
- (BCMA)
conjugated with a
cytotoxic agent,
maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug
conjugate binds to BCMA on
myeloma cell...
-
Oxford BioTherapeutics Ltd.
Seattle Genetics'
proprietary monomethyl auristatin E or MMAE-based antibody-drug
conjugate technology, emplo**** in brentuximab...
